Folylpolyglutamate Synthetase Inhibitors
6 drugsAbout Folylpolyglutamate Synthetase
Folylpolyglutamate Synthetase (FPGS) is an enzyme essential for folate metabolism. It catalyzes the ATP-dependent addition of glutamate residues to folate, creating polyglutamated forms that act as cofactors for nucleotide biosynthesis and amino acid metabolism.
FPGS is a therapeutic target in oncology because of its role in rapidly dividing cells. However, there is currently no genetic evidence directly linking variations in the FPGS gene to specific disease risks.
FPGS is targeted by 6 FDA-approved small molecule drugs, including PEMETREXED (ALIMTA), PEMFEXY, and AXTLE, all for oncology indications. These drugs are developed by companies such as Eli Lilly, Eagle Pharms, and Qilu Pharm Hainan.
Strategic Insights
ℹ️ How we calculate- phase2 represents biological uncertainty with 43% completion.
Top Folylpolyglutamate Synthetase Drugs
Six companies have approved drugs targeting FPGS, including Qilu Pharm Hainan and Eli Lilly.
The presence of multiple players suggests moderate competition, but also established market demand.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| ALIMTA | Eli Lilly | 2004 | 2 |
| PEMFEXY | EAGLE PHARMS | 2020 | 2 |
| PEMETREXED FOR INJECTION | Dr. Reddy's | - | 2 |
Folylpolyglutamate Synthetase Drug Modality Landscape
Modalities
Routes of Administration
Folylpolyglutamate Synthetase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or PROTACs could provide differentiation in this space.
Folylpolyglutamate Synthetase Clinical Trials 718 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 197 | 82 | 40 | 75 | 67% |
| Phase 2 | 325 | 94 | 78 | 150 | 55% |
| Phase 3 | 183 | 57 | 26 | 98 | 69% |
| Phase 4 | 13 | 6 | 3 | 4 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
8 Phase 3 trials testing approved Folylpolyglutamate Synthetase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Folylpolyglutamate Synthetase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Folylpolyglutamate Synthetase Drug Approval Timeline (2004 - 2024)
The first drug targeting FPGS was approved in 2004 (ALIMTA), with the most recent approval in 2024 (AXTLE).
Continued approvals suggest ongoing interest, but a 21-year span indicates potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 6 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 543 clinical trials targeting Folylpolyglutamate Synthetase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities